Italia markets close in 5 hours 33 minutes

Terumo Corporation (TRUMF)

OTC Markets OTCPK - OTC Markets OTCPK Prezzo differito. Valuta in USD.
Aggiungi a watchlist
16,57+0,12 (+0,70%)
Alla chiusura: 03:51PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente16,45
Aperto17,03
Denaro0,00 x 0
Domanda0,00 x 0
Min-Max giorno16,57 - 17,03
Intervallo di 52 settimane12,48 - 19,84
Volume1.019
Media Volume1.715
Capitalizzazione25,256B
Beta (mensile su 5 anni)0,50
Rapporto PE (ttm)36,82
EPS (ttm)0,45
Prossima data utili07 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)0,17 (1,00%)
Data ex dividendo27 set 2024
Stima target 1AN/D
  • GlobeNewswire

    Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

    U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest

  • GlobeNewswire

    Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

    Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat